Peptone Expands Leadership Team with Key Executive Hires
LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.
- LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
- "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
- Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
- He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.